Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mosaic HIV-1 envelope trimer immunogens are a series of engineered recombinant proteins designed to address the high genetic diversity of HIV-1. These immunogens utilize "mosaic" sequences—computationally optimized sequences designed to maximize the representation of potential T-cell and B-cell epitopes from diverse global HIV-1 strains. They are typically presented in the **SOSIP** format, which stabilizes the envelope (Env) protein in its native-like, prefusion trimeric conformation through a disulfide bond (SOS) and a proline mutation (IP). By mimicking the structure of the functional HIV-1 spike, these trimers aim to elicit broadly neutralizing antibodies (bNAbs) against conserved sites of vulnerability, such as the CD4 binding site, the V3-glycan patch, and the apex. These immunogens are often administered as a cocktail (e.g., MT1, MT2, and MT3) to broaden the immune response across multiple HIV-1 clades.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on mosaic HIV-1 envelope trimer immunogens.